High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL

It remains challenging in chronic lymphocytic leukemia (CLL) to distinguish between patients with favorable and unfavorable time-to-first treatment (TTFT). Additionally, the downstream protein correlates of well-known molecular features of CLL are not always clear. To address this, we selected 40 CL...

Descripción completa

Detalles Bibliográficos
Autores principales: Hengeveld, Paul J., Kolijn, P. Martijn, Demmers, Jeroen A.A., Doff, Wouter, Dubois, Julie M.N., Rijken, Melissa, Assmann, Jorn L.J.C., van der Straten, Lina, Boiten, Henk Jan, Gussinklo, Kirsten J., Valk, Peter J.M., Faber, Laura M., Westerweel, Peter E., Kater, Arnon P., Levin, Mark-David, Langerak, Anton W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508458/
https://www.ncbi.nlm.nih.gov/pubmed/37731707
http://dx.doi.org/10.1097/HS9.0000000000000951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10508458/
https://www.ncbi.nlm.nih.gov/pubmed/37731707
http://dx.doi.org/10.1097/HS9.0000000000000951

Ejemplares similares